Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, CEO, will present at the Grand Challenges in Parkinson's Disease Conference on September 28-29, 2022, in Grand Rapids, Michigan. The presentation focuses on IkT-148009, a potential disease-modifying therapy for Parkinson's disease, detailing outcomes from multiple pre-clinical studies. The session will occur at 3:00 PM EDT on September 28, highlighting the therapy's impact on multi-organ repair. Inhibikase is dedicated to developing treatments for neurodegenerative disorders related to Parkinson's disease.
- None.
- None.
BOSTON and ATLANTA, Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Grand Challenges in Parkinson's Disease Conference. The event is being held in Grand Rapids, Michigan and virtually between September 28-29, 2022.
Presentation Details:
Abstract Title: Clinical studies of a potential disease-modifying agent for Parkinson's disease: IkT-148009
Session: Session 3: c-Abl Inhibition
Presentation Date & Time: September 28, 2022, 3:00pm-3:30pm EDT
Location: Van Andel Institute
The presentation will detail the outcomes from multiple pre-clinical animal model studies of IkT-148009 as a potential disease modifying therapy for inherited and idiopathic Parkinson's disease, including results indicating multi-organ repair using once daily oral therapy.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Company Contact:
Milton H. Werner, Ph.D.
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-grand-challenges-in-parkinsons-disease-conference-301630209.html
SOURCE Inhibikase Therapeutics, Inc.
FAQ
What is the focus of Inhibikase Therapeutics' presentation at the Grand Challenges in Parkinson's Disease Conference?
When will Inhibikase Therapeutics present at the Grand Challenges in Parkinson's Disease Conference?
Where is the Grand Challenges in Parkinson's Disease Conference being held?
What are the key outcomes related to IkT-148009 discussed in the presentation?
What is the ticker symbol for Inhibikase Therapeutics?
